HYDERGINE
LOE ApproachingNDASUBLINGUALTABLET
Approved
Nov 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is a small-molecule sublingual tablet with an unknown mechanism of action approved in 1953 by Novartis. Specific indications are not detailed in available data. The product's mechanism and clinical utility remain incompletely characterized in this dataset.
LOE Approaching
Loss of exclusivity is imminent, signaling a contracting brand team and focus on generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYDERGINE offers limited career advancement given the LOE-approaching lifecycle and zero linked job opportunities. Roles will focus on managing decline, defending market share, and preparing for generic competition rather than brand growth.
Brand ManagerField Sales Representative
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.